China Universal Asset Management Co. Ltd. Buys 4,338 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

China Universal Asset Management Co. Ltd. grew its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 63.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,142 shares of the biotechnology company’s stock after acquiring an additional 4,338 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Ascendis Pharma A/S were worth $1,664,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Signaturefd LLC increased its stake in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. raised its holdings in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares during the last quarter. Searle & CO. bought a new position in Ascendis Pharma A/S in the 2nd quarter valued at approximately $205,000. Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth $288,000.

Wall Street Analyst Weigh In

ASND has been the topic of several recent analyst reports. Citigroup increased their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. TD Cowen increased their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Down 0.7 %

NASDAQ ASND opened at $129.44 on Tuesday. Ascendis Pharma A/S has a 12 month low of $86.54 and a 12 month high of $161.00. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of -13.47 and a beta of 0.64. The company’s 50 day moving average is $134.56 and its two-hundred day moving average is $134.11.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.2 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.